VIR supply chain intelligence for Vir Biotechnology, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Vir Biotechnology, Inc. (VIR) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| INSTITUTE-FOR-RESEARCH-IN-BIOMEDICINE | INSTITUTE-FOR-RESEARCH-IN-BIOMEDICINE | 92% | Under the terms of the IRB Research Agreement, IRB performs certain research activities for Humabs |
| SANOFI-S-A | SANOFI-S-A | 90% | Under the terms of Vir Bio's licensing agreement with Sanofi, Vir Bio will share a portion of certain collaboration proceeds received from Astellas with Sanofi |
| THE-ROCKEFELLER-UNIVERSITY | THE-ROCKEFELLER-UNIVERSITY | 90% | Pursuant to the Rockefeller Agreement, we entered into an exclusive license agreement with The Rockefeller University, or Rockefeller |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ALNY graph: , the lead party will be responsible for all costs and expenses incurred in connection with the development and commercialization of the collaboration product… |
| SNY | Sanofi | 72% | Reciprocal relationship from SNY graph: . The license agreement entered into with Vir Biotechnology, Inc. in September 2024 led to the derecognition of the ProXTen intangible asset. For further infor… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from VIR graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from VIR graph: Reciprocal relationship from SNYNF … |
| SNYNF | Sanofi | 72% | candidates, the competitive position of our product candidates, and import or export of raw materials and product used in our drug development, clinical manufacturing and future commercial activities… |
| XLO | Xilio Therapeutics, Inc. | 72% | Reciprocal relationship from XLO graph: ction with creating an independent sales and marketing organization. Developing a sales and marketing organization requires significant investment and substant… |
| XNCR | Xencor, Inc. | 72% | Reciprocal relationship from XNCR graph: Reciprocal relationship from VIR graph: Reciprocal relationship from XNCR graph: Reciprocal relationship from VIR graph: Reciprocal relationship from XNCR gra… |
| AAPL | Apple Inc. | 62% | Reciprocal relationship from AAPL graph: ce. When a component or product uses new technologies, initial capacity constraints may exist until the suppliers’ yields have matured or their manufacturing … |
| BTI | British American Tobacco p.l.c. | 62% | Reciprocal relationship from BTI graph: Reciprocal relationship from VIR graph: Reciprocal relationship from BTI graph: Reciprocal relationship from VIR graph: Reciprocal relationship from BTI graph:… |
| VHC | VirnetX Holding Corporation | 62% | Reciprocal relationship from VHC graph: Reciprocal relationship from VIR graph: Reciprocal relationship from VHC graph: 524 3,820 Cash flows from financing activities: Payment of payroll taxes on equ… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES | USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES | 95% | USAspending awards from Department of Health and Human Services: $65,867,804 across 1 awards. 75A50122C00081 VIR BIOTECHNOLOGY - OTA FOR PRE-EXPOSURE PROPHYLACTIC MONOCLONAL ANTIBODIES FOR THE PREVEN… |
| ASTELLAS-US-LLC | ASTELLAS-US-LLC | 92% | Vir Bio has agreed to grant to Astellas, subject to certain intellectual property rights of Sanofi S.A. (Sanofi), an exclusive license to develop, manufacture, commercialize and otherwise exploit VIR-5500 |
| NORGINE | NORGINE | 92% | The Company determined that Norgine is a customer with respect to the delivery of Norgine License |
| NORGINE-PHARMA-UK-LIMITED | NORGINE-PHARMA-UK-LIMITED | 92% | In exchange, Vir Bio will receive an initial reimbursement of development costs from Norgine in the amount of EUR 55 million and is eligible to receive up to EUR 495 million in clinical, regulatory a… |
| GATES-FOUNDATION | GATES-FOUNDATION | 90% | The Company accounted for the common stock issued to the Gates Foundation based on its fair market value on the closing date |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ALNY graph: Reciprocal relationship from VIR graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from VIR graph: clinical programs, the ability of col… |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | clinical programs, the ability of collaborators to successfully develop our licensed product candidates, competition, manufacturing capability and commercial viability. In addition, under our some of… |
| SNYNF | Sanofi | 72% | e of Contents VIR BIOTECHNOLOGY, INC. Notes to Consolidated Financial Statements $ $ Less: Segment expenses (1) Cost of revenue Research and development Personnel (2) Licenses, collaborations and con… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from VIR graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from VIR graph: Reciprocal relationship from SNYNF … |
| AMUNIX-PHARMACEUTICALS-INC | AMUNIX-PHARMACEUTICALS-INC | 62% | asonably believes may threaten the success of the project. 105 Table of Contents VIR BIOTECHNOLOGY, INC. Notes to Consolidated Financial Statements Concurrently with the execution of the grant agreem… |
| BRII-BIOSCIENCES-LIMITED | BRII-BIOSCIENCES-LIMITED | 62% | n our clinical programs, the ability of collaborators to successfully develop our licensed product candidates, competition, manufacturing capability and commercial viability. In addition, under our l… |
| COMPANY-LLC | COMPANY-LLC | 62% | tive 119,031 174,441 (55,410) Restructuring, long-lived assets impairment and related charges 34,995 13,559 21,436 Total operating expenses 661,370 770,485 (109,115) Loss from operations (587,165) (6… |
| ENCENTRIO-THERAPEUTICS-INC | ENCENTRIO-THERAPEUTICS-INC | 62% | n our clinical programs, the ability of collaborators to successfully develop our licensed product candidates, competition, manufacturing capability and commercial viability. In addition, under our l… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| VIR-DEBT-13360 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2019-12-31. |
| VIR-DEBT-13359 | Warrants outstanding: 2049000 | 90% | xbrl warrant detail from xbrl 2019-12-31. |
| VIR-DEBT | Debt stack $95.6M | 90% | Market cache reports total debt of $95.6M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| VIR-OWNER-BLACKROCK-INC | BlackRock, Inc. | 90% | 13F overlay lists BlackRock, Inc. as top holder; 257 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| EDIT | Editas Medicine, Inc. | 100.00 | 2 | |
| ATOS | Atossa Therapeutics, Inc. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| DBVTF | DBV TECHNOLOGIES | 100.00 | 2 | |
| BTI | British American Tobacco p.l.c. | 100.00 | 1 | ['supplier'] |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| DYN | Dyne Therapeutics, Inc. | 100.00 | 2 | |
| AAPL | Apple Inc. | 100.00 | 1 | ['supplier'] |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| VEEV | Veeva Systems Inc. | 100.00 | 2 | |
| SVA | Sinovac Biotech Ltd. | 100.00 | 2 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 2 |